Provided by Tiger Fintech (Singapore) Pte. Ltd.

Omeros

8.42
+0.56007.12%
Post-market: 8.420.00000.00%16:23 EDT
Volume:373.07K
Turnover:3.12M
Market Cap:487.94M
PE:-3.71
High:8.54
Open:8.02
Low:7.94
Close:7.86
Loading ...

BRIEF-Omeros Corporation Receives Commitment Of Over $4 Million From Nida For Further Development Of The Company’S Oms527 Program To Treat Cocaine Use Disorder

Reuters
·
13 Mar

Omeros Corporation Receives Commitment of Over $4 Million From Nida for Further Development of the Company’s Oms527 Program to Treat Cocaine Use Disorder

THOMSON REUTERS
·
13 Mar

Top Premarket Decliners

MT Newswires Live
·
07 Mar

Investors Look for Signs of Tariff Easing as US Futures Rise Modestly Pre-Bell

MT Newswires Live
·
05 Mar

Omeros announces results for narsoplimab expanded access program

TipRanks
·
21 Feb

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Business Wire
·
14 Feb

OMER S.p.a. Receives ‘Buy’ Rating Following Strategic Luxury Train Project and Anticipated Revenue Growth

TIPRANKS
·
13 Feb

BRIEF-Omeros Corporation Announces Upcoming Presentations Detailing Outcomes Of Narsoplimab Treatment For Ta-Tma

Reuters
·
10 Feb

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for Ta-Tma Under an Expanded Access Program

THOMSON REUTERS
·
10 Feb

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Business Wire
·
10 Feb

Institutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the company

Simply Wall St.
·
10 Feb

OMER S.p.A. Receives Buy Rating: Strategic Expansion and Market Potential Highlighted

TIPRANKS
·
28 Jan

Needham Remains a Hold on Omeros (OMER)

TIPRANKS
·
17 Jan

New Analysis of Omeros' Narsoplimab to Treat Complications From Stem Cell Transplant Support Results

MT Newswires Live
·
17 Jan

Omeros Is Maintained at Buy by D. Boral Capital

Dow Jones
·
17 Jan

BRIEF-Omeros Announces Update On Statistical Analysis Of Narsoplimab Pivotal Trial Primary Endpoint

Reuters
·
16 Jan